Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

MicroStrategy’s Bitcoin Bet Intensifies as Index Exclusion Looms

Robert Sasse by Robert Sasse
September 15, 2025
in Analysis, Bitcoin, Crypto Stocks, S&P 500
0
Strategy Stock
0
SHARES
140
VIEWS
Share on FacebookShare on Twitter

MicroStrategy continues to double down on its monumental cryptocurrency position, reinforcing its status as the world’s largest corporate holder of Bitcoin. However, this aggressive accumulation strategy comes at a cost, as the company faces continued exclusion from the prestigious S&P 500 index despite meeting formal eligibility requirements.

Persistent Bitcoin Acquisition

The business intelligence firm executed another significant purchase between September 2nd and 7th, acquiring 1,955 Bitcoin at a total cost of $217.4 million. This latest investment brought the average purchase price to approximately $111,196 per coin.

MicroStrategy’s treasury now holds an unprecedented 638,460 Bitcoin, valued at roughly $71 billion at current market prices. The company’s total investment in cryptocurrency amounts to approximately $47.2 billion, reflecting an average acquisition cost of $73,880 per Bitcoin. These recent purchases were funded through the sale of corporate stock and convertible notes.

Index Committee Rejection

In a move that surprised market observers, the S&P 500 index committee declined to include MicroStrategy in its benchmark index during the September rebalancing period. This decision came despite the company meeting the necessary market capitalization thresholds and reporting positive quarterly earnings.

The exclusion appears rooted in concerns over the extreme volatility of MicroStrategy’s earnings, which directly correlate with Bitcoin price fluctuations. The S&P 500 traditionally favors companies with diversified revenue streams and stable financial performance. This rejection denies MicroStrategy access to substantial passive investment flows from index funds and ETFs that automatically track the benchmark index.

Should investors sell immediately? Or is it worth buying Strategy?

Leadership Defends Strategy

Executive Chairman Michael Saylor remains undeterred, presenting compelling performance metrics to justify the company’s approach. According to Saylor, MicroStrategy’s Bitcoin strategy has generated an annualized return of 91 percent, significantly outperforming notable tech giants. By comparison, Nvidia has achieved 72 percent while Tesla posted 32 percent over the same period.

With capital costs of 14 percent and Bitcoin returns of 55 percent, the company’s leadership maintains that their mathematical model supports continued accumulation.

Technical Pressures Mount

Despite impressive theoretical returns, MicroStrategy shares face significant technical headwinds. The stock currently trades below key technical indicators and maintains a clear downward trajectory.

Equity researchers at TD Cowen maintained their “Buy” recommendation but reduced their price target from $680 to $640, acknowledging the persistent volatility concerns. The company’s extreme concentration in Bitcoin remains the primary risk factor for investors considering the stock.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from February 8 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Next Post
Bruker Stock

Bruker Faces Investor Backlash After Surprise Equity Offering

Chevron Stock

Chevron Navigates Strategic Overhaul Amid Divergent Investor Views

Enphase Energy Stock

Enphase Energy Faces S&P 500 Removal in Major Index Shakeup

Recommended

UBS Stock

UBS Share Buyback Fails to Impress Amid Regulatory Fears

3 months ago
IBM Stock

IBM’s UFC Partnership Showcases AI Capabilities in Live Sports

3 months ago
ImmunityBio Stock

ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress

6 days ago
BioNTech Stock

BioNTech’s Billion-Euro Forecast Shift Stuns Market

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Trending

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

by Jackson Burston
February 8, 2026
0

Investors in Rock Tech Lithium are in a holding pattern, with all eyes fixed on a pending...

Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com